Tasly Pharmaceutical Group Co., Ltd.

Tasly Biopharmaceuticals Co., Ltd.

Xiaohui Ma

Shunnan Zhang

Yonghong Zhu

He Sun

Xijun Yan

Naifeng Wu

Yi He

Kaijing Yan

Xiaolin Bai

Ting Li

Lei Li

Shuiping Zhou

Min Han

Jing Wang

Lanlan Zhang

Xiaodan Cao

Lulu Yan

Genbei Wang

Lihua Zhang

Wangyi Zhou

Yuanpeng Jin

Xinxin Li

Wei Li

Jian Li

Yan Chen

Wei Sun

Ping Li

Peng Liu

Wensheng Zhang

Guocheng Wang

Zhengliang Ye

Lihong Zhou

Yanyong Liu

Yibo Wang

Hai'ou Dong

Zhixin Guo

Lijun Fan

Chen Chen

Hua Yang

Wei Zhou

Chenming Li

Changwen Li

Jing Li

Ping Tai

Yongjie Jin

Yuanyuan Wang

Lianwen Qi

Ruijing Huang

Fenglian Zhang

Minchao Qi

Zhexuan Yang

Jing Yu

Xuejun Luo

Henry Sun

Sen Lin

Yiqian Zhang

Jun Han

Shuming Li

Xiaopeng Chen

Jiawen Shi

Xiaoqing Li

Jingjing Zhang

Guoyong Jia

Baoqing Fan

Yanchuan Li

Wenlei Li

Pengyin Wang

Jianping Han

Hongfang Cui

The invention relates to a method of treatment comprising administering a long-acting mutant human fibroblast growth factor to a subject in need thereof. The said long-acting mutant human fibroblast growth factor is mPEG-CH—NH-mFGF21, wherein mFGF21 consists of SEQ ID NO: 1, and the said new use consists of a method of treating non-alcoholic steatohepatitis.

Method of treating nash using a long-acting mutant human fibroblast growth factor

A pharmaceutical composition is prepared from the following raw materials (in parts by weight): silybin (8.75-60), phospholipid (15-65), a Pu'er tea extract (25-200), and vitamin E (6.25-40). The composition has the effect of treating non-alcoholic fatty liver diseases.

Pharmaceutical composition containing silybin and VE

The present invention belongs to the technical field of biological pharmacy, and particularly relates to a long-acting HM-3 fusion protein molecule and an application thereof. In the present invention, on the basis of the sequence of HM-3 molecule, an active polypeptide HM-3 and derivatives thereof are linked to a human Fc (IgG) fragment or a fragment of an Fc (IgG) mutant directly or by a linker peptide (Linker), thus forming a novel molecular entity. The general formula of the molecular entity is (HM-3)-Linker-Fc(IgG), Fc(IgG)-Linker-(HM-3), or (HM-3)-Linker-Fc(IgG)-Linker-(HM-3). The fusion protein effectively prolongs the half-life of HM-3, is low in cost and overcomes the major problem of druggability of small peptides. Therefore, the fusion protein of the present invention may serve as a potential drug for the treatment of autoimmune diseases, neovascular diseases, osteoarthritis and the like.

HM-3 fusion protein and application thereof

Disclosed are a pharmaceutical composition and an application thereof. The pharmaceutical composition of the present invention comprises the following components in parts by weight: 2-20 parts of phenolic acids, 0.5-5 parts of flavonoids, 0.005-0.5 part of tanshinones, 5-20 parts of saponins, and 10-18 parts of volatile oils. The pharmaceutical composition has the functions of protecting against myocardial damage and treating heart failure.

Pharmaceutical composition and application thereof

Pharmaceutical composition containing silybin and ve

Disclosed is an application of substituted cinnamamide derivatives in the preparation of anti-anxiety medications, the substituted cinnammide derivatives are compounds having the structure of formula (I) or pharmaceutically acceptable salts thereof, wherein, Ris &#x2014;H, &#x2014;OH, &#x2014;F, &#x2014;Cl, &#x2014;Br, &#x2014;I, &#x2014;OCH, &#x2014;OCF, &#x2014;OCHF, &#x2014;OCHF, &#x2014;CF, &#x2014;CHF, &#x2014;CHF, &#x2014;CH, &#x2014;CHCH, &#x2014;CFCH, &#x2014;CN, &#x2014;NO, &#x2014;NHor &#x2014;COOR; Ris H, C-Clinear alkyl, C-Cbranched alkyl, C-Ccyclic alkyl, C-Chydroxyalkyl or a N-substituted piperazine-derived group; or Ris a group forming with adjacent Y a tetrahydropyrrolyl group, a piperidyl group or a cyclohexanimido group. 

Application of substituted cinnamamide derivatives in preparation of anti-anxiety medication

The present invention relates to the medical field, specifically a salvianolic acid T as described in structural formula (I), a chiral isomer thereof, a preparation method therefor, pharmaceutical compositions, antioxidants, and free radical scavengers thereof, and a use of the compound. 

Salvianolic acid compound T, preparation method therefor, and use thereof

Disclosed is a pharmaceutical composition containing silibinin, which is prepared from the following bulk drugs by weight ratio: 8.75-60 parts of silibinin, 15-65 parts of phospholipid, and 25-200 parts of Pu'er tea extract. The drug has the function of treating non-alcoholic fatty liver.

Pharmaceutical composition containing silibinin

Disclosed are a pharmaceutical composition for treating non-alcoholic fatty liver and a method for preparing same. The composition is prepared from the following hulk drugs by weight ratio: 8.75-60 parts of silibinin, 15-65 parts of phospholipid, 25-200 parts of Pu'er tea extract, and 5-50 parts of radix puerariae extract.

Pharmaceutical composition containing silibinin and pueraria root extract

A pharmaceutical composition for treating non-alcoholic fatty liver diseases consists of a silybin-phospholipid complex preparation and Pu'er tea/tea product according to a weight ratio of 0.5-2.5:0.3-10, wherein the silybin-phospholipid complex capsule preparation and the Pu'er teat/tea product are separately packaged.

Pharmaceutical composition containing silybin

A pharmaceutical composition for treating non-alcoholic fatty liver diseases. The pharmaceutical composition is prepared from 8.75-60 parts by weight of silybin, 15-65 parts by weight of phospholipid, 25-150 parts by weight of a Pu'er tea extract, and 10.425-60 parts by weight of L-carnitine.

Pharmaceutical composition containing silybin and L-carnitine

A pharmaceutical composition. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 8.75-60 parts of silybin, 15-65 parts of phospholipid, 25-200 parts of a Pu'er tea extract, 6.25-40 parts of vitamin E, and 8.3-60 parts of L-carnitine. The composition can be used for treating non-alcoholic fatty liver diseases.

Pharmaceutical composition containing silybin, VE and L-carnitine

A traditional Chinese medicine composition and preparation thereof for treating cardiovascular diseases is provided. The traditional Chinese medicine composition consists of: by weight percentage, phenolic acid derivatives 30%&#x2dc;80%, tanshinones 2%&#x2dc;10% and saponins 15%&#x2dc;60%.

Traditional Chinese medicine composition

The present invention relates to substituted cinnamamide derivatives, the method for preparing thereof and the use thereof. Each of said derivatives has a structure of formula (I). The method for preparing the substituted cinnamamides and their derivatives of the present invention is also disclosed. Substituted piperonal derivatives are selected as starting materials to prepare the substituted cinnamamide derivatives of the present invention by Wittig reaction and acid-amine condensation reaction. Further, a use of the present compounds in preventing and treating depressive-type mental diseases is disclosed. 

Substituted cinnamamide derivative, preparation method and use thereof

The present invention relates to an andrographolide enteric targeting micropellet and a method for preparation thereof; furthermore, the present invention also relates to uses of andrographolide and andrographolide enteric targeting micropellets in preparation of a pharmaceutical for treatment of inflammatory bowel disease.

Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof

Growing community of inventors

Tianjin, China

Xiaohui Ma